Intravesical nanocrystalline silver decreases experimental bladder inflammation

Area of Science:

• Urology
• Inflammation Research
• Nanomedicine

Background:

• Interstitial cystitis is a chronic inflammatory bladder condition causing pain and urinary dysfunction.
• Current treatments for interstitial cystitis are limited, necessitating novel therapeutic approaches.
• Nanocrystalline silver exhibits anti-inflammatory properties that warrant investigation for bladder inflammation.

Purpose of the Study:

• To evaluate the efficacy of intravesical nanocrystalline silver in an experimental model of bladder inflammation.
• To assess the impact of nanocrystalline silver on key inflammatory markers, including histamine and tumor necrosis factor-alpha.

Main Methods:

• Female Sprague-Dawley rats received intravesical instillations of varying concentrations of nanocrystalline silver or phosphate-buffered saline.
• Bladder inflammation was induced using protamine sulfate and lipopolysaccharide.
• Urine and bladder tissue were analyzed for histamine and tumor necrosis factor-alpha levels, respectively.

Main Results:

• A 1% concentration of nanocrystalline silver significantly reduced urine histamine levels compared to controls.
• Treatment with 1% nanocrystalline silver led to a significant decrease in bladder tumor necrosis factor-alpha release.
• Nanocrystalline silver at 1% also reduced bladder inflammation and mast cell activation, with effects persisting for at least four days.

Conclusions:

• Intravesical administration of 1% nanocrystalline silver effectively mitigates experimental bladder inflammation.
• The observed reduction in histamine, tumor necrosis factor-alpha, and mast cell activation suggests a therapeutic benefit.
• Nanocrystalline silver presents a potential, non-toxic treatment option for interstitial cystitis.